首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
首頁 > 市場調查報告書 > 生物科技 > 分子標靶治療學 > 途徑研究(Pathway-Based Approach) 能否克服目標藥物研發的問題呢？
產業/市場分類
生物科技 (1470)
分子標靶治療學 (51)
生技設備 (321)
生物材料 (55)
生物標記 (157)
以基因為基之藥物開發 (201)
再生醫學 (120)
抗體和免疫 (187)
個人化醫學 (54)
基因治療學和RNAi (101)
市場調查報告書

途徑研究(Pathway-Based Approach) 能否克服目標藥物研發的問題呢？

Can Pathway-Based Approaches Overcome the Problems of Target-Based Drug Discovery?

出版商 Decision Resources, Inc.
出版日期 2006年06月 商品編碼 41359
內容資訊 英文 22 Pages
價格
本報告書已不再販售

本報告已在2011年12月21日停止出版。

簡介

製藥企業及生物科技企業在藥物研發上投資了莫大的金額，然而卻沒有得到相對的研究成果。現在企業已經重新評估藥物研發的研究策略，並且正在研商轉向使用途徑研究的可能性。

廣泛調查醫療業界的美國專業市調公司 Decision Resources Inc. （總公司：麻州），調查與分析目標藥物研發的問題與途徑研究的效果，並有系統地出版綜合報告書 "Can Pathway-Based Approaches Overcome the Problems of Target-Based Drug Discovery?" 。

此報告書使用22頁的篇幅，針對途徑研究的近年動向、應用途徑研究在藥物研發上的醫藥品研究開發的途徑策略影響等，進行一連串地探討。此報告書的概略架構如下所示。

說明

傳統途徑研究的成功

新途徑知識與研究的必要性

單一通路的解明與藥劑目標的明確化

  • 技術
    • 酵母雙雜合分析
    • Tandem Affinity Purification
    • RNAi
  • 策略
    • Cellzome的TNF-α/NF-kB單一變換通路研究
    • Hybrigenics的Drosophila單一變換通路研究

基於途徑的藥劑篩選技術與策略

  • BioImage的再分布技術
  • Bionaut的Sentinel Line技術
  • BioSeek的BioMAP系統

基於Novartis途徑的藥物研發策略

企業焦點

  • Bionaut Pharmaceuticals
  • BioSeek
  • Cellzome
  • BioImage
  • Hybrigenics

基於途徑的藥物研發展望

目錄

Abstract

After the human genome was sequenced, pharmaceutical and biotechnology companies hoped that their enormous investment in drug discovery and development programs--$51.3 billion in 2005--would yield higher R&D productivity. However, the industry's target-based research approach has failed to generate many drugs that work via novel mechanisms of action, and drugs that fail late in clinical trials significantly drive up the overall cost of drug development. Companies are now reevaluating their drug discovery research strategies, implementing or considering a shift to a pathway-based approach in the hopes of unlocking the promise of genomics-based drug discovery. By studying the routes by which drugs act on a system (i.e., a signaling pathway or network) rather than simply scrutinizing a specific target, companies hope to better understand how a disease progresses, which they hope will in turn lead to better-designed and more effective therapeutic strategies. In this report, we discuss recent progress in pathway-based drug discovery. We review studies aimed at expanding researchers' knowledge of key pathways and those that use whole-pathway screening methods. We also highlight the application of pathway-based methods to drug discovery and translational medicine and discuss the impact of pathway-based strategies on pharmaceutical R&D

Table of Contents

Introduction

The Success of Traditional Pathway Studies

The Need for New Pathway-Based Knowledge and Approaches

Elucidating Signaling Pathways and Identifying Drug Targets

  • Technologies
    • Yeast Two-Hybrid Assay
    • Tandem Affinity Purification
    • RNAi
  • Strategies
    • Cellzome's Study of the TNF-��/NF-�Н Signal Transduction Pathway
    • Hybrigenics' Study of Signal Transduction Pathways in Drosophila

Pathway-Based Drug Screening Technologies and Strategies

  • BioImage's Redistribution Technology
  • Bionaut's Sentinel Line Technology
  • BioSeek's BioMAP Systems
  • Avalon Pharmaceuticals' Pathology-Based Screens

Novartis's Pathway-Based Drug Discovery Strategy

Corporate Highlights

  • Bionaut Pharmaceuticals
  • BioSeek
  • Cellzome
  • BioImage
  • Hybrigenics

Outlook for Pathway-Based Drug Discovery

Back to Top